Ovarian cancer vaccine shows promise in early trial
NCT ID NCT04739527
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a vaccine called DCP-001 in 17 women with a serious type of ovarian cancer who had already completed standard treatment. The goal was to see if the vaccine is safe and can boost the immune system to recognize and fight cancer cells. Researchers measured immune responses and monitored for side effects and cancer recurrence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UMCG
Groningen, Provincie Groningen, 9713GZ, Netherlands